Evidence map›Paper›PMID 24190586›Full record

ArticlePsychopharmacology2014

Overlapping striatal sites mediate scopolamine-induced feeding suppression and mu-opioid-mediated hyperphagia in the rat.

Michelle L Perry, Wayne E Pratt, Brian A Baldo

Abstract read
In one paragraph

Article in Psychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Genetics and Epigenetics of Eating Disorders.Advances in genomics and genetics
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Michelle L PerryMolecular and Cellular Pharmacology, University of Wisconsin-Madison, 6001 Research Park Blvd, Madison, WI, 53719, USA, mlperry@wisc.edu.
Wayne E Pratt
Brian A Baldo
University of Wisconsin–Madison · USWake Forest University · US

Funding

Prefrontal cortex-hypothalmus interactions and feedingR01MH074723 · NIMH · UNIVERSITY OF WISCONSIN-MADISON · PI BALDO, BRIAN A · 2007 to 2019
$3.4M
OPIOID SYSTEMS IN VENTRAL STRIATUM AND FOOD REWARDR01DA009311 · NIDA · UNIVERSITY OF WISCONSIN-MADISON · PI BALDO, BRIAN A · 1995 to 2008
$1.9M
Striatal Acetylcholine-Opioid Interactions and FeedingF31DA023775 · NIDA · UNIVERSITY OF WISCONSIN-MADISON · PI PERRY, MICHELLE L · 2007 to 2010
$123k
NIDA NIH HHS F31 DA 023775NIDA NIH HHS F31 DA023775NIDA NIH HHS R01 DA 009311NIDA NIH HHS R01 DA009311NIMH NIH HHS R01 MH 074723NIMH NIH HHS R01 MH074723
6 · The paper itself

Abstract

rationaleIntra-striatal infusions of the muscarinic antagonist, scopolamine, markedly suppress feeding; however, the underlying mechanisms are unclear. Recent findings suggest that scopolamine influences opioid-dependent mechanisms of feeding modulation. Robust mu-opioid-mediated feeding responses are obtained in anterior, ventral sectors of the striatum with progressively weaker effects posteriorly and dorsally. One might therefore expect the effects of scopolamine to conform to similar boundaries, but a systematic mapping of scopolamine-induced feeding suppression has not yet been undertaken.

objectiveThis study aimed to assess the overlap between the striatal sites mediating scopolamine-induced feeding suppression and mu-opioid-induced hyperphagia.

methodsDose-effect functions for scopolamine (0, 1, 5, and 10 μg) were obtained in the nucleus accumbens (Acb), anterior dorsal striatum (ADS), and posterior dorsal striatum (PDS) in three different groups of rats. In the same subjects, the mu-opioid receptor agonist (D-Ala2-N-MePhe4, Glyol)-enkephalin (DAMGO; 0.25 μg) was infused on a separate test day. The dependent variables were food and water intake, ambulation, and rearing.

resultsThe greatest dose sensitivity for scopolamine-induced feeding suppression was observed in the Acb. Only the highest dose was effective in the ADS, and no effects were seen in the PDS. Water intake and general motor activity were not altered by scopolamine in any site. DAMGO infusions produced hyperphagia only in the Acb.

conclusionsThese results support a model in which the behavioral effects of muscarinic blockade are limited by the same anatomical constraints that govern mu-opioid receptor-mediated control of feeding. These constraints are likely imposed by the topographic arrangement of feeding-related afferent inputs and efferent projections of the striatum.

Indexed as

Analgesics, OpioidAnimalsCorpus StriatumDose-Response Relationship, DrugEnkephalin, Ala(2)-MePhe(4)-Gly(5)-Feeding BehaviorHyperphagiaMaleMuscarinic AntagonistsNucleus AccumbensRatsRats, Sprague-DawleyReceptors, Opioid, muScopolamineAnalgesics, OpioidEnkephalin, Ala(2)-MePhe(4)-Gly(5)-Muscarinic AntagonistsReceptors, Opioid, muScopolamine

Identifiers

PMID24190586
PMCPMC3945211
OpenAlexW2094043259

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.